Rhythm Pharmaceuticals Inc (RYTM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.97B
Last updated: Nov 17, 2026 at 4:35 PM ET
Rhythm Pharmaceuticals Inc (RYTM) Statistics
Rhythm Pharmaceuticals (RYTM) has a market cap of $7.97B and an enterprise value of $8.04B. It kept -69.03% of revenue as net income over the last 12 months. Revenue grew 61.04% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 0.79% above the market cap, as debt exceeds cash.
| Market Cap | $7.97B |
|---|---|
| Enterprise Value | $8.04B |
| Latest price (Nov 17, 2026) | $116.61 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 28.7x and 91.5x. Its year-end P/S ranged from 26.3x to 158.9x from 2021 to 2025.
| P/S Ratio | 28.7x |
|---|---|
| Forward P/S | 24.1x |
| P/B Ratio | 91.5x |
| P/TBV Ratio | 112.9x |
Price Statistics
The stock is up 17.30% over 52 weeks and trades 19.88% above its 50-day average.
| Beta (1Y) | 1.20 |
|---|---|
| 52-Week Change | +17.30% |
| 1-Month Change | +32.17% |
| 3-Month Change | +0.76% |
| 6-Month Change | +33.71% |
| 5-Year Change | +704.26% |
| Total Return (1Y) | +17.30% |
| Total Return (3Y CAGR) | +51.06% |
| Total Return (5Y CAGR) | +59.15% |
| Return vs SPY (1Y) | +4.46% |
| Max Drawdown (1Y) | -35.54% |
| Max Drawdown (3Y) | -35.54% |
| Sharpe Ratio (1Y) | 0.28 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $97.27 |
| 200-Day Average | $97.31 |
| 52-Week Range | $74.50 to $122.20 |
| RSI (14 Days) | 63.5 |
| Average Volume (20 Days) | 1.91M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.78x current liabilities, and total debt is 1.17x shareholder equity.
| Current Ratio | 2.78x |
|---|---|
| Quick Ratio | 2.57x |
| Debt / Equity | 1.17x |
| Interest Coverage | -10.31x |
Returns and Efficiency
Return on invested capital is -98.64% and return on equity is -220.32% over the last 12 months.
| Return on Equity (ROE) | -220.32% |
|---|---|
| Return on Assets (ROA) | -43.74% |
| Return on Invested Capital (ROIC) | -98.64% |
| Return on Capital Employed (ROCE) | -64.34% |
| ROA (5Y Average) | -46.27% |
| Asset Turnover | 0.59x |
| Inventory Turnover | 1.07x |
| Receivables Turnover | 7.06x |
| Cash Conversion Cycle | 244 days |
Scores
RYTM has an Altman Z-Score of 15.22, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 15.22 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $280.75M over the last 12 months.
| Revenue | $280.75M |
|---|---|
| Revenue Growth (YoY) | +61.04% |
| Gross Profit | $247.69M |
| Operating Income | -$187.25M |
| Pretax Income | -$192.24M |
| Net Income | -$193.81M |
| EBIT | -$188.03M |
| Reported EPS (TTM) | -$2.90 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 19.85% of the $443.13M in total assets.
| Cash and Equivalents | $39.98M |
|---|---|
| Total Debt | $102.67M |
| Net Debt | $62.69M |
| Net Debt Per Share | $0.91 |
| Working Capital | $268.47M |
| Shareholder Equity | $87.97M |
| Book Value Per Share | $1.27 |
| Tangible Book Value | $71.29M |
| Tangible Book Per Share | $1.03 |
| Total Assets | $443.13M |
| Total Liabilities | $241.59M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$81.79M |
|---|---|
| FCF Per Share | -$1.20 |
| Depreciation and Amortization | $6.47M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -66.70%.
| Gross Margin | 88.23% |
|---|---|
| Operating Margin | -66.70% |
| Pretax Margin | -68.48% |
| Net Margin | -69.03% |
| EBIT Margin | -66.98% |
| Gross Margin (5Y Average) | 87.89% |
Growth
Revenue grew 100.23% a year over 3 years.
| Revenue Growth (3Y CAGR) | +100.23% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -14.83% |
| Tangible Book Per Share Growth (2Y CAGR) | -14.69% |
Dividends and Yields
RYTM does not pay a dividend.
| Buyback Yield | -0.03% |
|---|---|
| Shareholder Yield | -0.03% |
Peer Position
Against 9 similar companies, RYTM has the 3rd highest P/S.
P/S RatioPeer median 11.1x
ROICPeer median -12.75%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +29.53%
| P/S Ratio | 28.7x vs 11.1x median |
|---|---|
| ROIC | -98.64% vs -12.75% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +61.04% vs +29.53% median |
Analyst Forecast
Consensus estimates put revenue growth at 74.56% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +74.56% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RYTM
What is RYTM's market cap?
Rhythm Pharmaceuticals has a market cap of $7.97B. Its enterprise value, which adds debt and subtracts cash, is $8.04B.
How many shares of RYTM are outstanding?
Rhythm Pharmaceuticals has 69.05M shares outstanding. The count is up 4.20% from a year earlier.
Does RYTM pay a dividend?
No. Rhythm Pharmaceuticals does not pay a dividend.
How much debt does RYTM have?
Rhythm Pharmaceuticals has $102.67M of total debt and $39.98M of cash and equivalents, a net debt position of $62.69M.
RYTM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors